S&P 500   3,311.34 (-0.31%)
DOW   29,057.99 (-0.44%)
QQQ   223.56 (-0.14%)
AAPL   317.56 (-0.04%)
FB   219.71 (-0.73%)
GOOGL   1,485.37 (+0.08%)
AMZN   1,879.29 (-0.43%)
CGC   24.39 (+1.12%)
NVDA   251.16 (+0.44%)
BABA   217.22 (-2.32%)
MU   59.13 (-0.07%)
GE   11.71 (+2.99%)
TSLA   563.25 (-1.11%)
AMD   51.13 (-0.58%)
T   38.59 (-1.15%)
ACB   2.04 (+0.00%)
F   9.05 (-1.31%)
NFLX   343.58 (+5.39%)
BAC   33.99 (-1.11%)
DIS   141.70 (-1.60%)
S&P 500   3,311.34 (-0.31%)
DOW   29,057.99 (-0.44%)
QQQ   223.56 (-0.14%)
AAPL   317.56 (-0.04%)
FB   219.71 (-0.73%)
GOOGL   1,485.37 (+0.08%)
AMZN   1,879.29 (-0.43%)
CGC   24.39 (+1.12%)
NVDA   251.16 (+0.44%)
BABA   217.22 (-2.32%)
MU   59.13 (-0.07%)
GE   11.71 (+2.99%)
TSLA   563.25 (-1.11%)
AMD   51.13 (-0.58%)
T   38.59 (-1.15%)
ACB   2.04 (+0.00%)
F   9.05 (-1.31%)
NFLX   343.58 (+5.39%)
BAC   33.99 (-1.11%)
DIS   141.70 (-1.60%)
S&P 500   3,311.34 (-0.31%)
DOW   29,057.99 (-0.44%)
QQQ   223.56 (-0.14%)
AAPL   317.56 (-0.04%)
FB   219.71 (-0.73%)
GOOGL   1,485.37 (+0.08%)
AMZN   1,879.29 (-0.43%)
CGC   24.39 (+1.12%)
NVDA   251.16 (+0.44%)
BABA   217.22 (-2.32%)
MU   59.13 (-0.07%)
GE   11.71 (+2.99%)
TSLA   563.25 (-1.11%)
AMD   51.13 (-0.58%)
T   38.59 (-1.15%)
ACB   2.04 (+0.00%)
F   9.05 (-1.31%)
NFLX   343.58 (+5.39%)
BAC   33.99 (-1.11%)
DIS   141.70 (-1.60%)
S&P 500   3,311.34 (-0.31%)
DOW   29,057.99 (-0.44%)
QQQ   223.56 (-0.14%)
AAPL   317.56 (-0.04%)
FB   219.71 (-0.73%)
GOOGL   1,485.37 (+0.08%)
AMZN   1,879.29 (-0.43%)
CGC   24.39 (+1.12%)
NVDA   251.16 (+0.44%)
BABA   217.22 (-2.32%)
MU   59.13 (-0.07%)
GE   11.71 (+2.99%)
TSLA   563.25 (-1.11%)
AMD   51.13 (-0.58%)
T   38.59 (-1.15%)
ACB   2.04 (+0.00%)
F   9.05 (-1.31%)
NFLX   343.58 (+5.39%)
BAC   33.99 (-1.11%)
DIS   141.70 (-1.60%)
Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NYSE:ABBV - AbbVie Stock Price, Forecast & News

$85.17
-2.04 (-2.34 %)
(As of 01/23/2020 01:18 PM ET)
Today's Range
$85.05
Now: $85.17
$87.07
50-Day Range
$86.43
MA: $88.57
$90.25
52-Week Range
$62.66
Now: $85.17
$91.99
Volume5.30 million shs
Average Volume6.31 million shs
Market Capitalization$125.95 billion
P/E Ratio39.25
Dividend Yield5.36%
Beta0.97
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.75 billion
Cash Flow$9.04 per share
Book Value($5.61) per share

Profitability

Net Income$5.69 billion

Miscellaneous

Employees30,000
Outstanding Shares1,478,820,000
Market Cap$125.95 billion
Next Earnings Date2/7/2020 (Confirmed)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a -- dividend on Friday, November 1st. Investors of record on Wednesday, January 15th will be given a dividend of $1.18 per share on Friday, February 14th. This represents a yield of 5.93%. The ex-dividend date of this dividend is Tuesday, January 14th. This is a positive change from AbbVie's previous -- dividend of $1.07. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie declared that its Board of Directors has initiated a share buyback program on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings data on Friday, November, 1st. The company reported $2.33 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.29 by $0.04. The firm earned $8.48 billion during the quarter, compared to the consensus estimate of $8.37 billion. AbbVie had a negative return on equity of 155.96% and a net margin of 9.90%. The firm's revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.14 EPS. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for AbbVie.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, February 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY19 earnings guidance on Friday, November, 1st. The company provided EPS guidance of $8.90-8.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.90.

What price target have analysts set for ABBV?

13 brokers have issued 1-year target prices for AbbVie's shares. Their forecasts range from $66.61 to $98.00. On average, they expect AbbVie's stock price to reach $86.33 in the next year. This suggests a possible upside of 1.3% from the stock's current price. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Has AbbVie been receiving favorable news coverage?

News stories about ABBV stock have trended somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AbbVie earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for AbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (0.07%), Hamlin Capital Management LLC (0.06%), Candriam Luxembourg S.C.A. (0.05%), Gateway Investment Advisers LLC (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.04%) and Janney Montgomery Scott LLC (0.04%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., Ambassador Advisors LLC, Candriam Luxembourg S.C.A., Commerzbank Aktiengesellschaft FI, Meag Munich Ergo Kapitalanlagegesellschaft MBH, OLD National Bancorp IN, TIAA FSB and Nisa Investment Advisors LLC. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

Which major investors are buying AbbVie stock?

ABBV stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Zurcher Kantonalbank Zurich Cantonalbank, Artemis Investment Management LLP, CHURCHILL MANAGEMENT Corp, 6 Meridian, Rhenman & Partners Asset Management AB, Manning & Napier Group LLC and Red Spruce Capital LLC. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $85.20.

How big of a company is AbbVie?

AbbVie has a market capitalization of $126.00 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com/.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,070 (Vote Outperform)
Underperform Votes:  757 (Vote Underperform)
Total Votes:  1,827
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel